CN105916855B - 作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物 - Google Patents

作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物 Download PDF

Info

Publication number
CN105916855B
CN105916855B CN201480073088.8A CN201480073088A CN105916855B CN 105916855 B CN105916855 B CN 105916855B CN 201480073088 A CN201480073088 A CN 201480073088A CN 105916855 B CN105916855 B CN 105916855B
Authority
CN
China
Prior art keywords
independently selected
substituted
occurrence independently
alkyl
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480073088.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105916855A (zh
Inventor
U·费拉帕蒂
C·P·达尔纳
刘培英
M·D·威特曼
B·C·皮尔斯
E·M·V·阿劳约
B·达斯古普塔
J·S·奈尔
S·K·贾纳基拉曼
C·R·拉沙姆雷迪
M·M·饶
A·M·S·S·卡鲁比
B·S·雷迪
P·拉加拉西尼
R·O·保拉
S·H·马海施瓦拉帕
S·库玛拉威尔
D·穆利克
R·西斯特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN105916855A publication Critical patent/CN105916855A/zh
Application granted granted Critical
Publication of CN105916855B publication Critical patent/CN105916855B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201480073088.8A 2013-11-14 2014-11-14 作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物 Expired - Fee Related CN105916855B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904116P 2013-11-14 2013-11-14
US61/904,116 2013-11-14
PCT/US2014/065594 WO2015073763A1 (en) 2013-11-14 2014-11-14 Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors

Publications (2)

Publication Number Publication Date
CN105916855A CN105916855A (zh) 2016-08-31
CN105916855B true CN105916855B (zh) 2019-03-15

Family

ID=51952052

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480073088.8A Expired - Fee Related CN105916855B (zh) 2013-11-14 2014-11-14 作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物
CN201480073199.9A Expired - Fee Related CN105916856B (zh) 2013-11-14 2014-11-14 作为酪蛋白激酶1d/e抑制剂的取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480073199.9A Expired - Fee Related CN105916856B (zh) 2013-11-14 2014-11-14 作为酪蛋白激酶1d/e抑制剂的取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物

Country Status (9)

Country Link
US (3) US9273058B2 (https=)
EP (2) EP3068784B1 (https=)
JP (2) JP6494622B2 (https=)
CN (2) CN105916855B (https=)
AR (1) AR098414A1 (https=)
ES (2) ES2744636T3 (https=)
TW (1) TW201605859A (https=)
UY (1) UY35834A (https=)
WO (2) WO2015073763A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605859A (zh) 2013-11-14 2016-02-16 必治妥美雅史谷比公司 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌
EP3112369A4 (en) * 2014-02-27 2017-09-20 The University of Tokyo Fused pyrazole derivative having autotaxin inhibitory activity
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2017198744A1 (en) * 2016-05-20 2017-11-23 F. Hoffmann-La Roche Ag Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018011163A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
WO2018064119A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
JP2020528062A (ja) * 2017-07-27 2020-09-17 江蘇恒瑞医薬股▲ふん▼有限公司 ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
TWI795440B (zh) 2017-09-15 2023-03-11 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
PE20201170A1 (es) 2017-11-01 2020-10-28 Bristol Myers Squibb Co Compuestos biciclicos en puente como moduladores del receptor farnesoide x
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019191166A1 (en) * 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2019228252A1 (zh) * 2018-06-01 2019-12-05 杭州阿诺生物医药科技有限公司 一种高活性csf1r抑制剂化合物
US10870648B2 (en) 2018-06-29 2020-12-22 Forma Therapeutics, Inc. Inhibiting CREB binding protein (CBP)
JP2022500466A (ja) 2018-09-21 2022-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
IL283190B2 (en) 2018-11-21 2025-08-01 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
MX2021008050A (es) 2019-01-11 2021-08-05 Shionogi & Co Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2).
CN111484498B (zh) * 2019-01-25 2021-05-14 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法
CN111484497B (zh) * 2019-01-25 2021-07-02 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
US20220081446A1 (en) * 2019-01-25 2022-03-17 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of 1,2,3-triazolo[1,5-a]pyrazines derivative and preparation method for crystal form
EP3921317B1 (en) 2019-02-07 2023-08-02 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
WO2020190791A1 (en) 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
EP4188928B1 (en) 2020-07-29 2024-07-24 Bayer Aktiengesellschaft Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
CN114057745A (zh) * 2020-07-29 2022-02-18 江苏恒瑞医药股份有限公司 一种三氮唑并[1,5-a]吡嗪制备方法及其应用
CA3189706A1 (en) * 2020-09-17 2022-02-24 Janssen Pharmaceutica Nv Casein kinase 1 delta modulators
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
WO2022166778A1 (zh) * 2021-02-04 2022-08-11 江苏恒瑞医药股份有限公司 一种衣壳蛋白抑制剂的药物组合物及其制备方法
EP4469457A4 (en) * 2022-01-27 2026-01-21 Broad Inst Inc CSNK1 SUBSTITUTE HETEROCYCLIC INHIBITORS
KR20250022711A (ko) * 2022-06-13 2025-02-17 시오노기 앤드 컴파니, 리미티드 다이하이드로피리딘온 유도체 또는 그 용매화물의 결정

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1556807A (zh) * 2001-09-19 2004-12-22 �㶫��������ҽҩ�ɷ����޹�˾ 化合物
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
CN1906194A (zh) * 2003-12-11 2007-01-31 安万特药物公司 作为酪蛋白激酶Iε抑制剂的取代的1H－吡咯并[3,2－b、3,2－c和2,3－c]吡啶－2－甲酰胺以及相关类似物
CN103168041A (zh) * 2010-06-03 2013-06-19 赛诺菲 3,4-二氢吡咯并[1,2-a]吡嗪-2,8(1h)-二甲酰胺衍生物、其制备方法及其治疗用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2346335B1 (en) 2008-09-24 2018-11-14 Basf Se Pyrazole compounds for controlling invertebrate pests
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CA2826464C (en) 2011-03-02 2020-07-28 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
TW201605859A (zh) 2013-11-14 2016-02-16 必治妥美雅史谷比公司 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1556807A (zh) * 2001-09-19 2004-12-22 �㶫��������ҽҩ�ɷ����޹�˾ 化合物
CN1906194A (zh) * 2003-12-11 2007-01-31 安万特药物公司 作为酪蛋白激酶Iε抑制剂的取代的1H－吡咯并[3,2－b、3,2－c和2,3－c]吡啶－2－甲酰胺以及相关类似物
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
CN103168041A (zh) * 2010-06-03 2013-06-19 赛诺菲 3,4-二氢吡咯并[1,2-a]吡嗪-2,8(1h)-二甲酰胺衍生物、其制备方法及其治疗用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Microwave-assisted synthesis, crystal structure of pyrazolo[1,5-a]pyrazin-4(5H)-ones and their selective effects on lung cancer cells;Ning Liu，等;《European Journal of Medicinal Chemistry》;20110315;第46卷(第6期);2359-2367 *
Synthesis and preliminary biological evaluation of novel pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as potential agents against A549 lung cancer cells;Jin-Hua Zhang，等;《Bioorganic & Medicinal Chemistry》;20081105;第16卷(第24期);10165-10171 *

Also Published As

Publication number Publication date
WO2015073763A1 (en) 2015-05-21
JP2016537369A (ja) 2016-12-01
CN105916855A (zh) 2016-08-31
US20160311824A1 (en) 2016-10-27
EP3068784A1 (en) 2016-09-21
TW201605859A (zh) 2016-02-16
ES2744636T3 (es) 2020-02-25
JP6494624B2 (ja) 2019-04-03
US9273058B2 (en) 2016-03-01
US20160122358A1 (en) 2016-05-05
WO2015073767A1 (en) 2015-05-21
US9598423B2 (en) 2017-03-21
EP3068784B1 (en) 2019-02-20
CN105916856B (zh) 2018-09-25
US20150133428A1 (en) 2015-05-14
AR098414A1 (es) 2016-05-26
JP6494622B2 (ja) 2019-04-03
ES2718218T3 (es) 2019-06-28
JP2016537366A (ja) 2016-12-01
UY35834A (es) 2015-05-29
CN105916856A (zh) 2016-08-31
EP3068785B1 (en) 2019-06-26
EP3068785A1 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
CN105916855B (zh) 作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物
CN109890797B (zh) 可用作抗癌剂的取代的碳核苷衍生物
JP6877407B2 (ja) Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
TWI730937B (zh) Ｇｐｒ６ 的四氫吡啶並吡調節劑
CN104470925B (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
CN106459003B (zh) 吡唑酰胺衍生物
CN114072407A (zh) 靶向prmt5的化合物
EP4225447A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator
CN108430992A (zh) 作为h-pgds抑制剂的喹啉-3-甲酰胺
CN113105475B (zh) 布鲁顿氏酪氨酸激酶的抑制剂及其使用方法
CN109195965A (zh) Wdr5蛋白质-蛋白质结合的抑制剂
CN110511209A (zh) 可用作激酶抑制剂的吲哚甲酰胺化合物
CN103288753A (zh) 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
CN105658653A (zh) 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CN106164076A (zh) 作为ROS1抑制剂的被取代的4，5，6，7‑四氢‑吡唑并[1，5‑a]吡嗪衍生物和5，6，7，8‑四氢‑4H‑吡唑并[1，5‑a][1，4]二氮杂环庚三烯衍生物
JP6954920B2 (ja) ブロモドメイン阻害薬としてのベンゾ［ｂ］フラン
CN109689664A (zh) 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物
WO2024149389A1 (zh) 取代桥环类抑制剂及其制备方法和应用
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
US20250289789A1 (en) Reversible lysine covalent modifiers of cdk2 and uses thereof
TW201410677A (zh) 縮環雜環化合物
AU2024367021A1 (en) Reversible lysine covalent modifiers of cdk2 and uses thereof
WO2025218811A1 (zh) pan-KRAS靶向蛋白降解剂及其制备方法和应用
HK40076948B (zh) Kras g12d抑制剂
HK40036987A (en) Atr inhibitor and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190315